

- [34] Imamura T, Yokosuka O, Kurihara T, et al. Distribution of hepatitis B viral genotypes and mutations in the core promoter and precore regions in acute forms of liver disease in patients from Chiba, Japan. *Gut* 2003;52:1630–7.
- [35] Kosaka Y, Takase K, Kojima M, et al. Fulminant hepatitis B: induction by hepatitis B virus mutants defective in the precore region and incapable of encoding e antigen. *Gastroenterology* 1991;100:1087–94.
- [36] Omata M, Ehata T, Yokosuka O, et al. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. *New Engl J Med* 1991;324:1699–704.
- [37] Sato S, Suzuki K, Akahane Y, et al. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. *Ann Intern Med* 1995;122:241–8.
- [38] Liang TJ, Hasegawa K, Rimon N, et al. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. *New Engl J Med* 1991;324:1705–9.
- [39] Karayiannis P, Alexopoulou A, Hadziyannis S, et al. Fulminant hepatitis associated with hepatitis B virus e antigen-negative infection: importance of host factors. *Hepatology* 1995;22:1628–34.
- [40] Laskus T, Persing DH, Nowicki MJ, et al. Nucleotide sequence analysis of the precore region in patients with fulminant hepatitis B in the United States. *Gastroenterology* 1993;105:1173–8.
- [41] Laskus T, Rakela J, Nowicki MJ, et al. Hepatitis B virus core promoter sequence analysis in fulminant and chronic hepatitis B. *Gastroenterology* 1995;109:1618–23.
- [42] Beasley RP, Hwang LY, Lin CC, et al. Incidence of hepatitis among students at a university in Taiwan. *Am J Epidemiol* 1983;117:213–22.
- [43] Kent GP, Brondum J, Keenlyside RA, et al. A large outbreak of acupuncture-associated hepatitis B. *Am J Epidemiol* 1988;127:591–8.
- [44] McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. *J Infect Dis* 1985;151:599–603.
- [45] Rinker J, Galambos JT. Prospective study of hepatitis B in thirty-two inadvertently infected people. *Gastroenterology* 1981;81:686–91.
- [46] Roumeliotou-Karayannis A, Tassopoulos N, Richardson SC, et al. How often does chronic liver disease follow acute hepatitis B in adults? *Infection* 1985;13:174–6.
- [47] Schomerus H, Wiedmann KH, Dolle W, et al. (+)-Cyanidanol-3 in the treatment of acute viral hepatitis: a randomized controlled trial. *Hepatology* 1984;4:331–5.
- [48] Tassopoulos NC, Papaevangelou GJ, Sjogren MH, et al. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. *Gastroenterology* 1987;92:1844–50.
- [49] Wands JR, Walker JA, Davis TT, et al. Hepatitis B in an oncology unit. *New Engl J Med* 1974;291:1371–5.
- [50] Bath GE, Scott TG, Sibbald CJ, et al. Acute hepatitis B in Edinburgh 1975–1992: a retrospective study in a population where human immunodeficiency virus is highly prevalent. *Epidemiol Infect* 1997;119:85–9.
- [51] Hou MC, Wu JC, Kuo BI, et al. Heterosexual transmission as the most common route of acute hepatitis B virus infection among adults in Taiwan—the importance of extending vaccination to susceptible adults. *J Infect Dis* 1993;167:938–41.
- [52] Lindh M, Horal P, Norkrans G. Acute hepatitis B in western Sweden—genotypes and transmission routes. *Infection* 2000;28:161–3.
- [53] Pebody RG, Ruutu P, Nohynek H, et al. Changing epidemiology of hepatitis B infection in Finland. *Scand J Infect Dis* 1999;31:251–4.
- [54] Struve J, Giesecke J, Lindh G, et al. Heterosexual contact as a major route for transmission of acute hepatitis B among adults. *J Infect* 1990;20:111–21.

Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection

Noboru Shinkai^{a,b}, Yasuhiro Tanaka^b, Etsuro Orito^b, Kiyooki Ito^b,
Tomoyoshi Ohno^c, Noboru Hirashima^c, Izumi Hasegawa^c,
Fuminaka Sugauchi^{a,b,c}, Ryuzo Ueda^b, Masashi Mizokami^{a,*}

^a Department of Clinical Molecular Informative Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

^b Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

^c Department of Gastroenterology, Chukyo Hospital, Japan

Received 15 June 2006; received in revised form 31 July 2006; accepted 9 August 2006

Available online 12 September 2006

Abstract

Background: Prolonged lamivudine therapy has two major problems: breakthrough hepatitis during treatment and relapse of aminotransferase (ALT) after cessation of the therapy. The aim of this study was to examine factors that could predict ALT flare after stopping lamivudine therapy.

Methods: We analyzed 22 Japanese patients with chronic hepatitis B infection, in whom lamivudine therapy was stopped after HBV DNA level had been gone undetectable (<3.7 LGE/ml) during at least six consecutive months. The post-treatment followed up was carried for 28 months in median (range 9–41). HBV core-related antigen (HBcrAg) assay was assessed using newly developed assay.

Results: After cessation of lamivudine therapy, 11 patients (50%) had relapsed (reactivation of serum ALT >80 IU/l, relapsers) and remaining 11 (50%) did not relapse (non-relapsers). In the univariate comparison of relapsers versus non-relapsers, HBcrAg level at lamivudine cessation point (4.5 ± 1.0 versus 3.4 ± 0.9 ; $p=0.0145$) has been shown as a significant predictive factor for non-relapse. All patients with HBcrAg <3.0 log U/ml at the cessation point had no ALT flares. Multivariate analysis on effects of 10 factors (age, sex, cirrhosis, pretreatment ALT level, HBV DNA level, HBcrAg level, mean months till undetectable HBV DNA, duration of undetectable HBV DNA and HBcrAg level at lamivudine cessation point), indicated that HBcrAg level at lamivudine cessation point <3.4 log U/ml was the only independent predictive factor for absence of the post-treatment relapse.

Conclusions: HBcrAg level at lamivudine cessation point might be useful as a prognostic predictor of response to lamivudine therapy cessation. The measurement of HBcrAg is a useful additional test for monitoring chronic HBV infection.

© 2006 Elsevier Ireland Ltd. All rights reserved.

Keywords: Hepatitis B virus; Hepatitis B virus core-related antigen; Lamivudine; Chronic hepatitis B virus infection

1. Introduction

Chronic hepatitis B virus (HBV) infection remains to be one of the major global health problems, affecting an estimate of 400 million people worldwide [1]. In a significant

proportion of cases, chronic infection progress to cirrhosis and liver failure as well as hepatocellular carcinoma (HCC) [2]. Lamivudine monotherapy is considered to be a therapeutic option for patients with chronic hepatitis B, irrespective of hepatitis B e antigen (HBeAg) status [3]. Viral resistance or viral breakthrough frequently associated in with prolongation of lamivudine therapy and caused by drug-resistant HBV mutants [4–7]. The breakthrough hepatitis may develop acute

* Corresponding author. Tel.: +81 18053 8289; fax: +81 18042 0021.

E-mail address: mizokami@med.nagoya-cu.ac.jp (M. Mizokami).

hepatitis flares, hepatic decompensation, and fatal hepatic failure [8–10]. Furthermore, the occurrence of lamivudine resistance increases the risk of HCC in antibody to HBeAg (anti-HBe) positive cirrhosis [11]. Hence, the Asia-Pacific consensus on the prevention and management of chronic hepatitis B and C has recommended that full HBeAg seroconversion, defined as undetectable HBeAg and HBV DNA with reappearance of anti-HBe, may be considered a suitable end point for lamivudine therapy. It is also recommended that lamivudine therapy should be maintained for 4–6 months after achieving HBeAg seroconversion to decrease the chance of posttreatment relapse [12].

Our recent study showed that highly sensitive HBV real-time detection direct test ($<0.7 \log \text{ IU/ml}$) can predict non-relapse after cessation of lamivudine monotherapy for chronic HBV infection [13], but the HBV real-time detection direct test is technically complicated and costly. On the other hand, an enzyme immunoassay (EIA) is a relatively simple method and provides a low cost and quantitative analysis with high reproducibility might have advantages over nucleic acid amplification assay if implied as an alternative. Recently, a chemiluminescence enzyme immunoassay (CLEIA) was developed for detection of hepatitis B virus core-related antigen (HBcrAg), which have positive correlation with HBV DNA levels in serum [14,15] and hepatocytes (submitted for publication). Furthermore, HBcrAg was shown as a clinically significant marker in monitoring the antiviral effect of lamivudine therapy [15,16]. Present study evaluated the usefulness of monitoring HBcrAg as a prognostic predictor of lamivudine therapy cessation in HBV-infected patients.

2. Patients, materials, and methods

2.1. Patients

A total of 22 patients with chronic hepatitis B, who were receiving lamivudine therapy during 1996 and 2005 at Nagoya City University Hospital (Nagoya) were enrolled in this study. Cirrhosis was determined mainly by ultrasonography (coarse liver architecture, nodular liver surface, and blunt liver edges) and evidence of hypersplenism (splenomegaly on ultrasonography), a platelet count $<100,000 \text{ mm}^{-3}$, or a combination thereof. Written informed consent was obtained from each patient. All were administered 100 mg of lamivudine per day for ≥ 6 months (median, 12 months; range, 6–43 months). The lamivudine therapy was stopped for each of the patients who had HBV DNA level maintained to be undetectable ($<3.7 \log$ genome equivalents [LGE]/ml), as measured by transcription-mediated amplification–hybridization protection assay (TMA–HPA; Chugai Diagnosis science) during >6 consecutive months of the follow up, whereas serum alanine aminotransferase (ALT) level did not exceed 40 IU/l (i.e., the upper limit of normal) during same period. In the HBeAg-positive patients, in addition to undetectable HBV DNA and normal ALT level, HBeAg-seronegative

maintained for ≥ 6 months was used as another criterion for stopping lamivudine therapy.

2.2. Methods

Serum HBsAg, HBeAg, and anti-HBe were measured by commercially available chemiluminescent enzyme immunoassay kit (Fujirebio Inc., Tokyo, Japan). The levels of HBV DNA in serum were determined using the TMA–HPA assay (Fujirebio Inc., Tokyo, Japan), with detection range is 3.7–8.7 LGE/ml and ALT were tested every months. HBcrAg was measured in serum using the CLEIA described previously [14]. Briefly, 150 μl of serum was incubated with 150 μl pretreatment solution containing 15% sodium dodecylsulfate at 60 °C for 30 min. After incubation at 60 ± 4 °C for 30 min, 150 μl pretreated specimen was added to the ferrite micro-particle (coated with monoclonal antibodies (HB44, HB61, and HB114) against denatured HBc and HBe antigens) solution in assay tube. After washing, two other alkaline phosphatase-labelled monoclonal antibodies against denatured HBcAg and HBeAg were added as secondary antibodies. Two hundred microliters substrate (AMPPD: (3-(2'-spiroadamantan)-4-methoxy-4-(3''-phosphoryloxy)phenyl-1,2-dioxetane disodium salt) (Applied Biosystems, Bedford, MA, USA) solution was added and the assay tube was incubated for 5 min at 37 °C. HBcrAg assay with The relative chemiluminescence intensity was measured with chemiluminescent enzyme immunoassay (CL-EIA) system for fully automated Lumipulse f CL-EIA analyzer (Fujirebio Inc., Tokyo, Japan), and the HBcrAg concentration was estimated by comparison to a standard curve generated using recombinant HBeAg. In the present study, the cutoff value was tentatively set at 3.0 log U/ml. Sera containing over 7.0 log U/ml of HBcrAg were diluted 10- or 100-fold in normal human serum and re-tested to obtain the end titer.

The end point of follow up was relapse after cessation of lamivudine therapy. Relapse was defined as reappearance of serum HBV DNA ($\geq 3.7 \text{ LGE/ml}$, as measured using the TMA–HPA assay) plus a reactivation in the serum ALT to $>80 \text{ U/l}$.

2.3. Statistical evaluation

Data are expressed as mean \pm S.D. or median (range). The primary focus of this analysis was to compare patients who experienced relapse with those who did not. The Mann–Whitney *U*-test was utilized to analyze quantitative data, the χ^2 test was used for qualitative data. The effect of age, sex, prevalence of cirrhosis, presence of HBeAg, pretreatment ALT level, pretreatment HBV DNA level, pretreatment HBcrAg level, mean months till undetectable HBV DNA, duration of HBV DNA level of $<3.7 \text{ LGE/ml}$, duration of lamivudine therapy, and HBcrAg level at cessation point were assessed by logistic regression analysis. *p*-Value of less than 0.05 were considered to be statistically significant.

Table 1
Characteristics of nominated 22 hepatitis B virus (HBV)-infected patients before lamivudine therapy

Characteristic	Value
Age, mean (years) \pm S.D.	45.0 \pm 9.3
Male sex, no. (%) of patients	12 (55)
HBeAg positive, no. (%) of patients	6 (27)
Genotype/subgenotype (Bj;Ce)	2:20
Cirrhosis, no. (%) of patients	4 (18)
Pretreatment ALT level, median U/l (range)	118 (47–554)
Pretreatment HBV DNA level, median LGE/ml (range)	6.9 (4.1–8.6)
Pretreatment HBcrAg level, median log U/ml (range)	5.8 (4.2–8.6)
Duration of lamivudine therapy, median months (range)	12 (6–43)
Posttreatment follow-up duration, median months (range)	28 (9–41)

Statistical analyses were performed using STATA Software (Stata Corporation, Texas, USA) version 7.0.

3. Results

Table 1 shows the pretreatment demographic and clinical characteristics of the 22 HBV-infected patients who received lamivudine therapy and stopped it. Before the lamivudine administration, serum HBV DNA was detectable in all patients, and HBeAg was positive in six (27%) of the them. HBV genotype B was determined in two patients and remaining 20 had genotype C-infection. All of the six HBeAg-positive patients stopped lamivudine therapy when their HBeAg became negative and their ALT levels were normalized and their HBV DNA levels were undetected by TMA-HPA (<3.7 LGE/ml) for more than 6 months. For the remaining 16 HBeAg-negative patients lamivudine administration was stopped after ALT levels were normalized and their HBV DNA levels were undetected by TMA-HPA for more than 6 months. After cessation of lamivudine therapy, 11 patients (50%) experienced relapse (relapsers) and 11 patients (50%) did not (non-relapsers). All patients




Fig. 1. Featured changes in HBcrAg, HBV DNA and ALT levels observed during clinical courses in (a) patient (no. 1) with ALT relapse and (b) patient (no. 2) without ALT relapse after the cessation of lamivudine therapy.

were then clinically observed after cessation of lamivudine monotherapy (median duration of posttreatment monitoring, 28 months; range, 9–41 months) (Table 2).

Fig. 1 shows typical cases with and without relapse after cessation of lamivudine therapy. Case no. 1 (Fig. 1a): a 46-year-old male with chronic hepatitis B (genotype C). Before receiving lamivudine, his laboratory data were as

Table 2
Characteristics patients with and without relapse after lamivudine therapy

Characteristic	Relapsers (n = 11)	Non-relapsers (n = 11)	p
Age, mean (years) \pm S.D.	44.8 \pm 9.3	45.2 \pm 9.8	2.82
Male sex, no. (%) of patients	4 (36)	8 (72)	0.08
HBeAg positive, no. (%) of patients	3 (27)	3 (27)	>0.999
Genotype Bj, no. (%) of patients	0 (0)	2 (18)	0.48
Cirrhosis	3 (27)	1 (9)	0.59
Pretreatment ALT level, mean (U/l) \pm S.D.	118 \pm 78	223 \pm 159	0.11
Pretreatment HBV DNA, mean (LGE/ml) \pm S.D.	6.6 \pm 1.1	6.5 \pm 1.3	0.87
Pretreatment HBcrAg level, mean (log IU/ml) \pm S.D.	6.0 \pm 1.1	5.5 \pm 1.3	0.26
Mean months till undetectable HBV DNA (months)	2.3 \pm 1.6	2.2 \pm 1.7	0.90
Duration of HBV DNA level of <3.7 mean LGE/ml (months)	13.2 \pm 4.2	13.5 \pm 11.0	0.15
HBcrAg level at lamivudine cessation point, mean (log U/ml) \pm S.D.	4.5 \pm 1.0	3.4 \pm 0.9	0.0145
Duration of lamivudine therapy, median months (range)	13 (11–28)	11 (6–46)	0.18
Posttreatment follow-up duration, median months (range)	29 (9–39)	23 (9–36)	0.32

follows: HBeAg positive; anti-HBe negative; ALT 242 IU/l; HBV DNA 7.9 LGE/ml; HBcrAg 8.36 log U/ml. The level of ALT decreased and was normalized at 4 months after treatment initiated. The level of HBV DNA decreased rapidly to undetectable at 4 months after treatment initiated, while HBcrAg levels decreased more slowly. At 7 months after treatment initiated, HBeAg became negative. Lamivudine therapy was stopped at 17 months after treatment initiated (undetectable HBV DNA for 13 months). At the point, HBcrAg level was 4.54 log U/ml. One month after treatment stopped, HBeAg was reemerged and HBV DNA was 6.2 LGE/ml. Two months after treatment stopped, the patient experienced ALT relapse (200 IU/l). Case no. 2 (Fig. 1b): a 59-year-old male with chronic hepatitis B (subgenotype Bj). Before receiving lamivudine, his laboratory data were as follows: HBeAg negative; anti-HBe positive; ALT 147 IU/l; HBV DNA 6.0 LGE/ml; HBcrAg 4.25 log U/ml. The level of ALT decreased and was normalized at 1 month after treatment initiated. The level of HBV DNA decreased rapidly and became undetectable at 1 month after treatment initiated. HBcrAg level also decreased to less than 3.0 log U/ml next month after treatment start. Lamivudine therapy was stopped at 14th months after treatment initiation. At the point, HBcrAg level was less than 3.0 log U/ml. Next month after treatment stopped, HBV DNA became detectable (5.5 LGE/ml) but has decreased; at 6 months after treatment stopped, the level of the HBcrAg remained less than 3.0 log U/ml. ALT was normal during 36 months after treatment stopped. Interestingly, two patients with subgenotype Bj in this study had no ALT relapse after the cessation of lamivudine therapy, probably due to lower pre-treatment HBV DNA and HBcrAg levels as well as persistently undetectable post-treatment HBcrAg levels (<3.0 log U/ml).

In a univariate comparison of patients who experienced relapse (relapsers) with those who did not (non-relapsers), a predictive factor for the non-relapse after cessation of lamivudine was HBcrAg level at the end of treatment (4.5 ± 1.0 versus 3.4 ± 0.9 ; $p = 0.0145$). The association with age, sex, presence of HBeAg before treatment, presence of cirrhosis, pretreatment ALT level, pretreatment HBV DNA level, pretreatment HBcrAg level, mean months till undetectable HBV DNA, duration of undetectable HBV DNA level (<3.7 LGE/ml), duration of lamivudine therapy was not significant. Interestingly, all six patient whose HBcrAg level <3 log U/ml at the end of treatment did not experienced relapse. Further multivariate analysis involving the 10 above factors effectors indicated that HBcrAg level of <3.4 log U/ml (OR, 103; 95% CI, 1.3–8242; $p = 0.042$), which was a mean value of non-relapsers, was the only independent predictive factor for absence of posttreatment relapse (Table 3). Six of seven patients whose HBcrAg level <3.4 log U/ml at the end of treatment did not experienced relapse [positive predictive value (PPV), 86%]. Ten of 15 patients whose HBcrAg level ≥ 3.4 log U/ml at the end of treatment experienced relapse [negative predictive value (NPV), 75%], which was higher

Table 3
Predictive factors for non-relapse in multivariate analysis

Factor	OR (95% CI) ^a	<i>p</i>
Age (years)	0.16 (0.90–1.10)	0.157
Male sex (%)	0.15 (0.001–17.2)	0.429
Cirrhosis (%)	19.4 (0.08–4932)	0.294
Pretreatment ALT level of >80U/l (%)	1.10 (0.02–63.7)	0.964
Pretreatment HBV DNA (LGE/ml)	0.81 (0.05–14.6)	0.886
Pretreatment HBcrAg level (log U/ml)	1.17 (0.24–5.64)	0.846
Mean months till undetectable HBV DNA (months)	1.32 (0.16–11.1)	0.800
Duration of HBV DNA level of <3.7 mean LGE/ml (months)	1.83 (0.15–22.4)	0.636
HBcrAg level of <3.4 log U/ml at lamivudine cessation point	103 (1.3–8242)	0.042
Duration of lamivudine therapy, mean (months) \pm S.D.	0.53 (0.42–6.5)	0.616




Fig. 2. Linear reduction of the HBcrAg levels is represented in mean value; comparison between relapsers and non-relapsers. At 6 months after treatment initiation and at the cessation point of lamivudine therapy, HBcrAg levels in the patients who experienced relapse were significantly higher than level of HBcrAg in the patients who did not.

than that (58%) when the HBcrAg level ≥ 3.0 log U/ml was applied as cut-off value.

Fig. 2 shows comparison of changes in the median levels of HBcrAg during lamivudine administration between relapsers and non-relapsers. The initial median level of HBcrAg in the relapsers was relatively higher than that in the non-relapsers. The levels of HBcrAg in the relapsers were significantly higher than that in the non-relapsers at 6 months after treatment initiation and at cessation points (5.0 ± 1.0 versus 3.5 ± 1.4 ; $p = 0.0156$ and 4.5 ± 1.0 versus 3.4 ± 0.9 ; $p = 0.0145$). Interestingly, log-reduction of HBcrAg levels at 6 months after lamivudine administration tended to be greater in non-relapsers than in relapsers (1.7 ± 0.9 versus 1.2 ± 0.8), but no significant. Similarly, log-reduction of HBcrAg at the cessation point also tended to be greater in non-relapsers than in relapsers (2.0 ± 0.9 versus 1.6 ± 1.1), but no significant.

4. Discussion

In this study, we showed that the HBcrAg level <3.4 log U/ml at the point of cessation of lamivudine monotherapy was the only independent predictive factor for absence of post-treatment relapse and better predictive value (PPV 86% NPV 75%) The CLEIA for the HBcrAg is eas-

ier and less costly approach in comparison to PCR-based or signal amplification assays and at the same time is more sensitive than common EIA. Furthermore, it is associated with lower risk of contamination and errors than the nucleic acid amplification assays. The chemiluminescence-based detection system is performed with an automatic microplate reader, takes only 1 h, and does not require a specially trained operator to perform the assay. It also allows quantitative analysis with high reproducibility [14].

Serum HBcrAg levels reflects the viral load in the natural course because these levels positively correlate with those of HBV DNA [14,15]. On the other hand, the character of HBcrAg is somewhat different from that of HBV DNA in patients undergoing anti-viral therapies such as lamivudine. That is, HBcrAg levels decrease significantly more slowly than those of HBV DNA after initiation of lamivudine administration [16]. One of the reasons is that HBcrAg concentration would correlate well with intrahepatic parameters such as Knobel necroinflammation and fibrosis scores, percentage of cells immunostained positive for cytoplasmic and nuclear HBcAg, and intrahepatic total HBV DNA and covalently closed circular DNA (cccDNA level) (submitted for publication).

Lamivudine is a potent nucleoside analogue which inhibits HBV reverse transcriptase, reducing production of HBV DNA-containing virions [17]. As the transcription or translation of viral mRNA is not inhibited by nucleoside analogue such as lamivudine, the production and secretion of HBeAg is not directly inhibited and may persist for a period of time. Moreover, it has been demonstrated that a 22 kDa truncated precore/core protein, which is also detected by the CLEIA assay for HBcrAg, is found in “empty” HBV DNA-negative Dane particles [18]. The production of these particles and HBeAg is not dependent on the formation of HBV DNA, but it reflects the level of transcription and translation of the HBV core/precore gene in the liver. Thus, it is reasonable to monitor HBcrAg level during lamivudine therapy, because the levels of HBcrAg may reflect an altered HBV replication status within the hepatocyte; lower HBcrAg levels in serum corresponding to lower cccDNA levels in hepatocyte could predict non-relapse after the cessation of lamivudine therapy.

In summary, the measurement of HBcrAg is a useful additional test for monitoring chronic HBV infection, allowing continuous monitoring especially in lamivudine-treated patients whose HBV DNA become undetectable by PCR.

References

- [1] Lai CL, Ratziu V, Yuen MF, et al. Viral hepatitis B. *Lancet* 2003;362(9401):2089–94.
- [2] Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. *Cancer* 1988;61(10):1942–56.
- [3] Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: summary of a workshop. *Gastroenterology* 2002;122:2092–3.
- [4] Chayama K, Suzuki Y, Kobayashi M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. *Hepatology* 1998;27(6):1711–6.
- [5] Lau DT, Khokhar MF, Doo E, et al. Long-term therapy of chronic hepatitis B with lamivudine. *Hepatology* 2000;32(4 Pt 1):828–34.
- [6] Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. *Gastroenterology* 2000;119(1):172–80.
- [7] Hadziyannis SJ, Papatheodoridis GV, Dimou E, et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. *Hepatology* 2000;32(4 Pt 1):847–51.
- [8] Liaw YF, Chien RN, Yeh CT, Tsai SL, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. *Hepatology* 1999;30(2):567–72.
- [9] Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. *Hepatology* 1998;27(6):1670–7.
- [10] Honkoop P, de Man RA, Niesters HG, et al. Clinical impact of lamivudine resistance in chronic hepatitis B. *J Hepatol* 1998;29(3):510–1.
- [11] Andreone P, Gramenzi A, Cursaro C, et al. High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance. *J Viral Hepat* 2004;11(5):439–42.
- [12] Conjeevaram HS, Lok AS. Management of chronic hepatitis B. *J Hepatol* 2003;38(Suppl 1):S90–S103.
- [13] Ito K, Tanaka Y, Orito E, et al. Predicting relapse after cessation of lamivudine monotherapy for chronic hepatitis B virus infection. *Clin Infect Dis* 2004;38(4):490–5.
- [14] Kimura T, Rokuhara A, Sakamoto Y, et al. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. *J Clin Microbiol* 2002;40(2):439–45.
- [15] Rokuhara A, Tanaka E, Matsumoto A, et al. Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment. *J Viral Hepat* 2003;10(4):324–30.
- [16] Tanaka E, Matsumoto A, Suzuki F, et al. Measurement of hepatitis B virus core-related antigen is valuable for identifying patients who are at low risk of lamivudine resistance. *Liver Int* 2006;26(1):90–6.
- [17] Wolters LM, Hansen BE, Niesters HG, et al. Viral dynamics in chronic hepatitis B patients during lamivudine therapy. *Liver* 2002;22(2):121–6.
- [18] Kimura T, Ohno N, Terada N, et al. Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa pre-core protein without C-terminal arginine-rich domain. *J Biol Chem* 2005;280(23):21713–9.

Gut

*An International Journal of
Gastroenterology and Hepatology*

LETTER

Interferon- β plus ribavirin for patients with hepatitis C virus genotype 1: a randomised pilot trial

M Enomoto, A Tamori, N Kawada, H Jomura, S Nishiguchi, T Saibara,
S Onishi, S Mochida, K Fujiwara

(Reprinted from GUT, January 2006, Vol 55, No 1, p 139-140)

BMJ
Publishing
Group

R

M

P

R

I

N

T

Interferon- β plus ribavirin for patients with hepatitis C virus genotype 1: a randomised pilot trial

The rate of sustained eradication of hepatitis C virus (HCV) in response to a combination of interferon- α and ribavirin remains unsatisfactory in patients with genotype 1 infection.¹ No effective alternative treatment is currently available for non-responders. Interferon- β is also a type I interferon commonly used to treat chronic HCV infection in Japan. A previous study showed that a 24 week course of therapy with interferon- β plus ribavirin resulted in sustained loss of HCV in three of nine patients with chronic hepatitis C.² However, the efficacy and safety of interferon- β combined with ribavirin has yet to be fully evaluated.

We report the results of a randomised pilot trial comparing interferon- β plus ribavirin

with interferon- α plus ribavirin in patients with HCV genotype 1 who poorly responded to interferon- α plus ribavirin. A total of 28 patients with HCV genotype 1 were given 6 MU of recombinant interferon- α 2b (Schering-Plough, Kenilworth, New Jersey, USA) by intramuscular injection daily for four weeks. Twenty seven patients (16 men and 11 women; mean age 47 (\pm 8) years) in whom HCV RNA was detected in serum on polymerase chain reaction at week 2 were included in this study and randomly assigned to receive one of two regimens from week 5. Fifteen patients continued to receive 6 MU interferon- α 2b intramuscularly, given daily from week 5 to week 8, and three times weekly from week 9 to week 24 (interferon- α group). The other 12 patients were assigned to 6 MU natural interferon- β (Toray Industries Inc., Tokyo, Japan), given by intravenous injection daily from week 5 to week 8, and three times weekly from week 9 to week 24 (interferon- β group). Ribavirin (Schering-Plough) was concurrently administered at a daily dose of 600 mg to patients who weighed 60 kg or less and 800 mg to those who weighed more than 60 kg. At the time of this study, a 24 week course of interferon- α plus ribavirin was commonly used in Japan. The data were analysed according to intention to treat.

Baseline characteristics of the patients in the treatment groups were similar. At week 4 of therapy, when treatment was randomly assigned, the proportion of patients without detectable HCV RNA in serum did not differ between the interferon- α group and interferon- β groups (table 1). The proportion of patients without HCV RNA in serum was higher in the interferon- β group than in the interferon- α group at week 12, but did not differ between the groups at the end of treatment (week 24). However, 24 weeks later (week 48), the proportion of patients with a sustained virological response was significantly higher in the interferon- β group than in the interferon- α group. During treatment, neutralising antibodies to interferon were detected in two patients in the interferon- α group and in no patients in the interferon- β group. Leucocyte, neutrophil, and platelet counts and haemoglobin concentrations were similar in two groups. Therapy was discontinued because of serious adverse events (including depression) in three patients in the interferon- α group; all 12 patients in the interferon- β group completed 24 weeks of treatment. The dose of ribavirin was reduced because of anaemia in eight patients in the interferon- α group and in four in the interferon- β group.

We enrolled patients who did not have a favourable early response to treatment with interferon- α and ribavirin. Antibodies to interferon, which sometimes develop in

patients given recombinant interferon- α , can cause resistance to therapy. Both interferon- α and - β bind to a common type I interferon receptor but utilise different regions of the receptor subunits for specific signalling pathways,³ potentially leading to distinct biological responses. An oligonucleotide array study has shown that some interferon stimulated genes are preferentially induced by interferon- β , but not by interferon- α .⁴ We thus believe that interferon- β might be beneficial for some patients who are resistant to interferon- α . A large randomised trial of peginterferon- α plus ribavirin versus interferon- β plus ribavirin for 48 weeks is being conducted in patients with HCV genotype 1 who do not have a virological response⁵ to 12 weeks of treatment with peginterferon- α and ribavirin.

In summary, a combination of interferon- β and ribavirin produced a significantly better sustained virological response than a combination of interferon- α and ribavirin in patients with HCV genotype 1 who were resistant to interferon- α plus ribavirin. Although the overall safety profiles of the two regimens were similar, the rates of treatment discontinuation and of reduction in the dose of ribavirin were lower in patients receiving interferon- β and ribavirin than in those receiving interferon- α and ribavirin.

Acknowledgement

Grant support was received from Ministry of Health, Labour, and Welfare, Japan.

M Enomoto, A Tamori, N Kawada, H Jomura
Department of Hepatology, Osaka City University
Medical School, Osaka, Japan

S Nishiguchi
Department of Internal Medicine, Hyogo College of
Medicine, Nishinomiya, Japan

T Saibara, S Onishi
Department of Gastroenterology and Hepatology,
Kochi Medical School, Kochi, Japan

S Mochida, K Fujiwara
Division of Gastroenterology and Hepatology, Internal
Medicine, Saitama Medical School, Saitama, Japan

Correspondence to: Dr S Nishiguchi, Division of Hepatobiliary and Pancreatic Diseases, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa, Nishinomiya, Hyogo 663-8501, Japan; nishiguc@hyo-med.ac.jp

doi: 10.1136/gut.2005.081935

Conflict of interest: None declared.

References

- 1 Dusheiko G, Barnes E, Webster G, *et al*. The science, economics, and effectiveness of combination therapy for hepatitis C. *Gut* 2000;47:159-61.
- 2 Kakumu S, Yoshioka K, Wakita T, *et al*. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. *Gastroenterology* 1993;105:507-12.
- 3 Domanski P, Nadeau OW, Platanius LC, *et al*. Differential use of the beta1 subunit of the type I interferon (IFN) receptor determines signaling specificity for IFNalpha2 and IFNbeta. *J Biol Chem* 1998;273:3144-7.
- 4 Der SD, Zhou A, Williams BR, *et al*. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. *Proc Natl Acad Sci U S A* 1998;95:15623-8.
- 5 Davis GL. Monitoring of viral levels during therapy of hepatitis C. *Hepatology* 2002;36(suppl 1):S145-51.

Table 1 Proportions of patients without detectable hepatitis C virus RNA in serum

	Interferon- α group (n = 15)	Interferon- β group (n = 12)	p Value (χ^2 test)
Week 4	4 (27%)	3 (25%)	0.92
Week 12	7 (47%)	10 (83%)	0.049
Week 24 (end of therapy)	10 (67%)	9 (75%)	0.64
Week 48	0 (0%)	3 (25%)	0.040

REVIEW

Hepatitis B Virus Genotypes and Response to Antiviral Therapy

MASARU ENOMOTO¹, AKIHIRO TAMORI¹,
SHUHEI NISHIGUCHI²

¹Department of Hepatology, Osaka City University Medical School, Osaka, Japan
²Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan

SUMMARY

Hepatitis B virus (HBV) infection is an important health problem worldwide. The virus has been classified according to 8 genotypes (A–H) based on sequence divergence. Most genotypes have specific geographic distributions; genotypes A and D are prevalent in Western Europe and North America, and genotypes B and C are prevalent in East Asia and Oceania. Currently accepted treatment for chronic hepatitis B includes interferon alpha, or the nucleoside/nucleotide analogues lamivudine and adefovir. The impact of HBV genotypes on response to antiviral therapy has been studied. HBV genotypes D and C are associated with a lower rate of favorable response to interferon alpha therapy than genotypes A and B, respectively. A study in Germany suggested that the rate of resistance to lamivudine was higher in patients with HBV genotype A infection than in patients with genotype D infection. No difference in the risk of lamivudine resistance is found between patients with genotype B and patients with genotype C. In patients with genotype C infection, however, virological response is worse during lamivudine therapy, and is also less durable after the discontinuation of therapy than in patients with genotype B infection. Determining the genotype could be helpful for predicting the outcome of antiviral therapy in patients with chronic hepatitis B. (Clin. Lab. 2006;52:43-47)

KEY WORDS

hepatitis B, genotype, adefovir, antiviral therapy, interferon, lamivudine

INTRODUCTION

Hepatitis B virus (HBV) affects more than 350 million people worldwide. It is the major causative agent for chronic hepatitis, cirrhosis, and hepatocellular carcinoma, accounting for 1 million deaths annually [1,2]. Currently available antiviral therapy for chronic hepatitis B includes the immunomodulator interferon alpha, and the nucleoside/nucleotide analogues lamivudine and adefovir dipivoxil [3,4]. In addition, entecavir has recently been licensed in the United States. A number of other nucleotide analogues, such as tenofovir, emtricitabine, telbivudine and clevudine, are now at the stage of clinical trials. Interferon alpha is expensive, and is often poorly tolerated. Long-term treatment with nucleoside/nucleotide analogues may induce the emergence of drug-resistant variants with mutations in the reverse

transcriptase (rt) domain of the HBV polymerase gene. For instance, mutations from methionine to isoleucine, valine or serine at amino acid rt204 in the tyrosine-methionine-aspartate-aspartate (YMDD) motif are associated with resistance to some nucleoside/nucleotide analogues including lamivudine [5–8].

HBV was traditionally classified into four subtypes (*adr*, *adw*, *ayr*, and *ayw*) based on antigenic determinants of hepatitis B surface antigen [9]. According to the Paris workshop on hepatitis B surface antigen subtypes, these subtypes were further divided into eight types (*adr*, *ayr*, *ayw1*, *ayw2*, *ayw3*, *ayw4*, *adw2*, and *adw4*) [10]. However, the clinical significance of HBV subtypes has not been established. With recent advances in molecular biology techniques, HBV has been classified according to 8 genotypes (A–H) based on sequence divergence in the entire genome exceeding 8% [11–14]. Most genotypes have specific geographic distributions. Genotype A is prevalent in Northwest Europe (including Germany), North America, and Central Africa. Genotypes B and C are common in Southeast Asia, China, Japan, and Oceania. Genotype B is further divided into two subgroups: “Bj” (corresponds to “B1” of the classi-

fication of Norder et al. [15]) which is exclusive to Japan, and "Ba" which is common in other countries in Asia [16]. Genotype D prevails in South Europe, the Middle East, and India, although this type has an almost worldwide distribution.

The contribution of HBV genotypes to therapeutic outcome has recently attracted the interest of researchers and clinicians. The clinical outcome of chronic HBV infection has been compared between genotypes A and D in Western countries, and between genotypes B and C in Asia. In general, genotypes D and C are associated with more severe liver disease than genotypes A and B, respectively [17,18]. The impact of HBV genotypes on the response to antiviral therapy has also been studied. In this article, we review the role of HBV genotypes with particular reference to the implications for therapy.

HBV GENOTYPES AND RESPONSE TO INTERFERON ALPHA

Zhang et al. [19] studied HBV genotypes in 35 hepatitis B e antigen (HBeAg)-negative chronic hepatitis B patients in France who had been treated with interferon alpha for a mean duration of 16 months (range, 3–40 months). The response to interferon, defined as sustained normalization of serum alanine aminotransferase (ALT) levels and significant decrease of viremia levels, was found in 7 (70%) of 10 patients with genotype A infection, compared with 10 (40%) of 25 patients with genotype D or E infection ($p = 0.001$). The rate of response to interferon was independent of both initial serum viral DNA levels and interferon doses.

In Germany, Erhardt et al. [20] determined the efficacy of interferon alpha in 165 consecutive patients with chronic replicative hepatitis B with different genotypes. Among them, 119 patients (72%) had HBeAg-positive and 46 (28%) had HBeAg-negative hepatitis B infection. Six months after the end of a 4- to 15-month course of interferon therapy, a sustained response, defined as normal ALT levels and negative HBV DNA in hybridization assay, was found in 38 (49%) of the 78 patients with genotype A infection, compared with 17 (26%) of the 66 patients with genotype D infection ($p < 0.005$). Multivariate logistic regression analysis identified HBV genotypes and pretreatment ALT levels as independent predictive parameters of response to interferon ($p < 0.009$ and $p < 0.02$, respectively).

Kao et al. [21] retrospectively studied 58 Taiwanese HBeAg-positive patients with genotype B or C infection who had been treated with interferon alpha for 24 weeks. The patients with genotype C infection had a higher serum ALT level than patients with genotype B infection. The rate of response to interferon, defined as normalization of serum ALT level and loss of HBeAg and HBV DNA 48 weeks post-treatment was 13/32 (41%) and 4/26 (15%) in genotype B and C patients, respectively. Younger age and genotype B infection were significant and independent variables for predicting the

response to interferon alpha treatment ($p = 0.001$ and 0.045 , respectively).

Wai et al. [22] performed a retrospective analysis of a previously reported randomized controlled trial to determine the effects of HBV genotype on the response to interferon alpha in ethnic Chinese patients with HBeAg-positive chronic hepatitis. Among the 66 patients with elevated pretreatment ALT level, an antiviral response, defined as sustained clearance of serum HBV DNA by direct spot hybridization and clearance of HBeAg at month 12, was achieved in 57% and 21% of patients treated with interferon alpha for 16 weeks ($p = 0.019$), compared with 25% and 8% of untreated controls ($p = 0.45$) with HBV genotype B and C, respectively. Multivariate analysis showed that genotype B and low pretreatment HBV DNA levels were independent predictors of antiviral response ($p = 0.001$ and 0.029 , respectively).

The attachment of a polyethyleneglycol moiety to interferon alpha produces a biologically active molecule, peginterferon alpha, with a long half-life and favorable pharmacokinetics. Janssen et al. [23] reported the results of a multicenter, randomized controlled trial of peginterferon alpha for HBeAg-positive chronic hepatitis B. For 266 patients (90 with genotype A, 23 with genotype B, 39 with genotype C, 103 with genotype D, and 11 with other types), 52-week treatment regimen was started with weekly doses of 100 μg peginterferon alpha-2b, and then during weeks 32 to 52, the dose of peginterferon was reduced to 50 μg per week. Although patients were randomly assigned peginterferon monotherapy or combination therapy with lamivudine, the rate of HBeAg loss 26 weeks post-treatment was similar between the two groups (49/136 [36%] vs 46/130 [35%]; $p = 0.91$). There was a significant difference in the sustained loss of HBeAg according to HBV genotype by univariate analysis ($p = 0.01$); 42 (47%) with genotype A and 10 (44%) with genotype B had sustainedly lost HBeAg, compared with 11 (28%) with genotype C and 26 (25%) with genotype D.

These results indicate that HBV genotypes D and C are associated with a lower rate of favorable response to interferon alpha therapy than genotypes A and B, respectively.

HBV GENOTYPES AND RESPONSE TO LAMIVUDINE

In a study conducted in Germany, Zöllner et al. [24] found that among 26 consecutive patients with chronic hepatitis B (20 were HBeAg-positive and 6 were HBeAg-negative), drug-resistant mutant variants developed in 7 of 13 carriers with *adw* and 1 of 13 carriers with *ayw* during 3 to 31 months of lamivudine treatment; the risk of lamivudine resistance was significantly higher in *adw* carriers than in *ayw* carriers ($p = 0.03$). In Germany, subtype *adw* corresponds to genotype A, and subtype *ayw* corresponds to genotype D. Zöllner et al.

[25] further studied the mutational pattern of the HBV polymerase gene in 41 patients during selection of lamivudine-resistant strains. Twenty-six patients (63%) carried resistant HBV genotype A and 15 patients (37%) carried resistant HBV genotype D. The rate of mutations from methionine to isoleucine at rt204 was significantly higher for genotype D (67%) compared with genotype A (19%), whereas mutations from methionine to valine at rt204 prevailed in genotype A (81% in genotype A vs 33% in genotype D; $p = 0.006$).

Buti et al. [26], however, reported that the proportion of lamivudine-resistant mutations did not differ between HBV genotypes A and D during longer term observation. Among the 27 patients in Spain with chronic hepatitis B (8 HBeAg-positive and 19 anti-HBe-positive) receiving lamivudine for a mean period of 24 months (range, 12–36 months), 16 had genotype A HBV (equivalent to *adw*) and 11 had genotype D (equivalent to *ayw*). At year 1 of therapy, the lamivudine-resistant variants were found more often in genotype A patients than in genotype D patients (7/16 [43%] vs 2/11 [18%]), but the difference was not significant. At year 2, the drug-resistant variants were found in 8 (53%) of the 15 genotype A patients and in 5 (55%) of the 9 genotype D patients, and at year 3, in 3 (75%) of the 4 genotype A and genotype D patients. The Kaplan–Meier estimate for the median time to lamivudine resistance in all 27 patients was 24 months, independent of HBV genotype.

Kao et al. [27] enrolled 31 consecutive Taiwanese patients with HBeAg who had been treated with lamivudine. During the study period, which ranged from 6 to 30 months, 3 (23%) of the 13 patients with genotype B infection and 2 (11%) of the 18 patients with genotype C infection had seroconversion to anti-HBe. Lamivudine-resistant mutant variants occurred in 2 (15%) patients from the genotype B group and 4 (22%) from the genotype C group ($p = 0.9$) after a mean duration of 9 months (range, 8–13 months).

In another study conducted in Taiwan, Chien et al. [28] examined the determinants of sustained HBeAg seroconversion after discontinuation of lamivudine. In a total of 82 HBeAg-positive patients who had achieved a complete response (defined as HBeAg seroconversion with HBV DNA seroclearance by hybrid capture assay and normal ALT levels) to a mean period of 16 months (range, 3–55 months) lamivudine therapy was followed-up. In 38 (61%) of the 62 patients with genotype B and 5 (25%) of the 20 patients with genotype C, complete response was sustained for 12 months after the end of therapy. The categorical analysis showed that patients with genotype B, age ≤ 36 years, and additional treatment over 8 months after HBeAg seroconversion had a higher sustained response to lamivudine.

Akuta et al. [29] determined the cumulative rate of emergence of drug-resistant mutant variants in 213 Japanese patients with chronic hepatitis B (108 were HBeAg-positive and 105 were HBeAg-negative) who had been treated with lamivudine for more than 1 year. Eight (3.8%) patients were infected with genotype A, 20

(9.4%) patients with genotype B, and 185 (86.9%) patients with genotype C. The emergence rate of lamivudine resistance was independent of the genotype, but was significantly higher in the *Ba* subgroup of HBV (66.7% at 2 years) than in the *Bj* subgroup (7.1% at 2 years, $p < 0.05$). In patients with genotype C infection, lamivudine-resistant variants emerged significantly more often in the HBeAg-positive state than in the HBeAg-negative state ($p < 0.05$). In contrast, the emergence rate was not associated with HBeAg status in patients with genotype B infection.

In summary, a study conducted in Germany suggested that the rate of emergence of resistance to lamivudine was higher in patients with HBV genotype A infection than in patients with genotype D infection. However, this result has not been confirmed by a longer term study. There is no difference between patients with genotype B and C for the risk of lamivudine resistance. In patients with genotype B infection, the virological response is better during lamivudine therapy, and is also more durable after the discontinuation of therapy than in patients with genotype C infection.

HBV GENOTYPES AND RESPONSE TO ADEFOVIR DIPIVOXIL AND NEW NUCLEOTIDE ANALOGUES

Westland et al. [30] examined HBV genotypes in patients with chronic hepatitis B who had been enrolled in 2 multinational phase III studies of adefovir dipivoxil. In the 269 patients (43 with genotype A, 52 with genotype B, 71 with genotype C, 96 with genotype D, and 7 with other types) who received 10 mg adefovir dipivoxil for 48 weeks, potent reductions in serum HBV DNA were observed regardless of HBV genotype, HBeAg status, or race; similarly, there was no statistical difference in HBeAg seroconversion rates between genotypes in these patients.

To date, the impacts of HBV genotype on the therapeutic response and emergence of drug-resistant variants in patients receiving entecavir or other nucleotide analogues at the stage of clinical trials have not yet been reported.

CONCLUSIONS

Differences in response to therapy with antiviral agents, including interferon alpha and lamivudine, do exist among different HBV genotypes. Genotype determination could be helpful for predicting the outcome of therapy in patients with chronic hepatitis B. However, we have to be aware that the genotype is not the only factor that determines whether a patient should be treated. In Asian countries, for example, the most prevalent genotype, genotype C, is associated with progressive liver disease; spontaneous remission of HBV infection occurs rarely in patients who chronically carry this

genotype [18]. Patients with genotype C often need to be treated with an antiviral agent, such as interferon alpha or lamivudine (which are currently available), even though the therapeutic response is expected to be poor. Further studies are needed to clarify the efficacy of new antiviral agents in patients with various genotypes.

References

- Maddrey WC. Hepatitis B—an important public health issue. *Clin Lab* 2001; 47: 51–5.
- Ganem D, Prince AM. Hepatitis B virus infection—natural history and clinical consequences. *N Engl J Med* 2004; 350: 1118–29.
- de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, Mele A, Paumgartner G, Pietrangelo A, Rodes J, Rosenberg W, Valla D; EASL Jury. EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002 Geneva, Switzerland. Consensus statement (long version). *J Hepatol* 2003; 39 (Suppl 1): S3–25.
- Lok AS, McMahon BJ; Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. *Hepatology* 2004; 39: 857–61.
- Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. *Hepatology* 1996; 24: 711–3.
- Kohmoto M, Enomoto M, Yano Y, Otani S, Minamitani S, Tamori A, Habu D, Takeda T, Shiomi S, Seki S, Arakawa T, Nishiguchi S. Detection of serum hepatitis B virus DNA by real-time quantitative polymerase chain reaction (TaqMan PCR) during lamivudine treatment: comparison with three other assays. *Hepatology Res* 2003; 26: 125–33.
- Enomoto M, Nishiguchi S, Seki S, Yamane T, Hino M. Adefovir dipivoxil to prevent exacerbation of lamivudine-resistant hepatitis B infection during chemotherapy for non-Hodgkin's lymphoma. *Am J Gastroenterol*. 2004; 99: 1619–20.
- Pas SD, Noppornpanth S, van der Eijk AA, de Man RA, Niesters HG. Quantification of the newly detected lamivudine resistant YSDD variants of Hepatitis B virus using molecular beacons. *J Clin Virol* 2005; 32:166–72.
- Le Bouvier GL, McCollum RW, Hierholzer WJ Jr, Irwin GR, Krugman S, Giles JP. Subtypes of Australia antigen and hepatitis-B virus. *JAMA* 1972; 222: 928–30.
- Courouce AM, Drouet J, Muller JY. Australia antigen subtypes identification. *Bibl Haematol*. 1976; 42: 89–127.
- Okamoto H, Tsuda F, Sakugawa H, Sastrosoewignjo RI, Imai M, Miyakawa Y, Mayumi M. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. *J Gen Virol* 1988; 69: 2575–83.
- Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. *Virology* 1994; 198: 489–503.
- Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, Rossau R. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. *J Gen Virol* 2000; 81: 67–74.
- Arauz-Ruiz P, Norder H, Robertson BH, Magnius LO. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. *J Gen Virol* 2002; 83: 2059–73.
- Norder H, Courouce AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, Robertson BH, Locarnini S, Magnius LO. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. *Intervirology* 2004; 47: 289–309.
- Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu S, Ishida T, Chutaputti A, Lai CL, Ueda R, Miyakawa Y, Mizokami M. Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. *J Virol* 2002; 76: 5985–92.
- Thakur V, Guptan RC, Kazim SN, Malhotra V, Sarin SK. Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent. *J Gastroenterol Hepatol* 2002; 17: 165–70.
- Orito E, Mizokami M, Sakugawa H, Michitaka K, Ishikawa K, Ichida T, Okanoue T, Yotsuyanagi H, Iino S. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. *Hepatology* 2001; 33: 218–23.
- Zhang X, Zoulim F, Habersetzer F, Xiong S, Trepo C. Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B. *J Med Virol* 1996; 48: 8–16.
- Erhardt A, Blondin D, Hauck K, Sagir A, Kohnle T, Heintges T, Haussinger D. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. *Gut* 2005; 54: 1009–13.
- Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. *J Hepatol* 2000; 33: 998–1002.
- Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg (+) chronic hepatitis than genotype C. *Hepatology* 2002; 36: 1425–30.
- Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW; HBV 99-01 Study Group; Rotterdam Foundation for Liver Research. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. *Lancet* 2005; 365:123–9.
- Zöllner B, Petersen J, Schroter M, Laufs R, Schoder V, Feucht HH. 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. *Lancet* 2001; 357: 934–5.
- Zöllner B, Petersen J, Puchhammer-Stockl E, Kletzmayer J, Sterneck M, Fischer L, Schroter M, Laufs R, Feucht HH. Viral features of lamivudine resistant hepatitis B genotypes A and D. *Hepatology* 2004; 39: 42–50.

26. Buti M, Cotrina M, Valdes A, Jardi R, Rodriguez-Frias F, Esteban R. Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine? *J Hepatol* 2002; 36: 445-6.
27. Kao JH, Liu CJ, Chen DS. Hepatitis B viral genotypes and lamivudine resistance. *J Hepatol* 2002; 36: 303-4.
28. Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. *Hepatology* 2003; 38: 1267-73.
29. Akuta N, Suzuki F, Kobayashi M, Tsubota A, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. *J Hepatol* 2003; 38: 315-21.
30. Westland C, Delaney W 4th, Yang H, Chen SS, Marcellin P, Hadziyannis S, Gish R, Fry J, Brosgart C, Gibbs C, Miller M, Xiong S. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. *Gastroenterology* 2003; 125: 107-16.

Correspondence: Akihiro Tamori, M.D., Ph.D.
 Department of Hepatology,
 Graduate School of Medicine,
 Osaka City University Medical School,
 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan.
 Tel: +81-6-6645-3811; Fax: +81-6-6645-3813
 E-mail: atamori@med.osaka-cu.ac.jp

Timing of interferon therapy and sources of infection in patients with acute hepatitis C

Kei Ogata^{a,*}, Tatsuya Ide^a, Ryukichi Kumashiro^a, Hiromitsu Kumada^b,
Hiroshi Yotsuyanagi^{c,1}, Kiwamu Okita^d, Yoshihiro Akahane^{e,2}, Shuichi Kaneko^f,
Hirohito Tsubouchi^{g,3}, Eiji Tanaka^h, Hisataka Moriwakiⁱ, Shuhei Nishiguchi^{j,4},
Shinichi Kakumu^k, Masashi Mizokami^l, Shiro Iino^m, Michio Sata^a

^a Second Department of Internal Medicine, Kurume University, Fukuoka, Japan

^b Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan

^c Department of Internal Medicine, Division of Gastroenterology and Hepatology, St. Marianna University School of Medicine, Kawasaki, Japan

^d Department of Gastroenterology and Hepatology, Yamaguchi University School of Medicine, Ube, Japan

^e First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan

^f Department of Gastroenterology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan

^g Second Department of Internal Medicine, Faculty of Medicine, The University of Miyazaki, Miyazaki, Japan

^h Department of Medicine, Shinshu University School of Medicine, Matsumoto, Japan

ⁱ First Department of Internal Medicine, Gifu University School of Medicine, Gifu, Japan

^j Department of Hepatology, Osaka City University, Graduate School of Medicine, Osaka, Japan

^k Department of Internal Medicine, GI Division, Aichi Medical University School of Medicine, Aichi, Japan

^l Department of Laboratory Medicine, Nagoya City University Medical School, Nagoya, Japan

^m Seizankai Kiyokawa Hospital, Tokyo, Japan

Received 13 June 2005; received in revised form 22 August 2005; accepted 31 August 2005

Available online 15 December 2005

Abstract

Background/Aims: Controversy over the selection of patients and optimum therapeutic method for acute hepatitis C has continued. The aims of this study were to investigate the source of infection, and to evaluate the timing of interferon (IFN) therapy in patients with acute hepatitis C in Japan.

Methods: The records of 102 patients from 12 facilities in Japan who developed acute hepatitis C after 1990 were investigated. In the patients treated with IFN, we performed multivariate analysis to investigate factors related to sustained virological response (SVR).

Results: Medical procedure was the most common source of infection, accounting for 32.4% in the 102 patients (33/102). Of 81 patients treated with IFN, 71 patients were followed after IFN therapy, and 57/71 (80.3%) had SVR. The SVR rate was significantly higher in patients treated with IFN within 24 weeks from onset of symptoms than the SVR rate in those treated after 25 weeks ($P=0.0016$). Multivariate analysis revealed that only the duration between onset of symptoms and initiation of IFN therapy (within 24 weeks) was related to SVR.

DOI of related article: [10.1016/j.hepres.2005.10.002](https://doi.org/10.1016/j.hepres.2005.10.002).

Abbreviations: HCV, hepatitis C virus; IFN, interferon; ALT, alanine aminotransferase; SVR, sustained virological response; Peg-IFN, pegylated interferon

* Corresponding author. Tel.: +81 942 31 7561; fax: +81 942 34 2623.

E-mail address: keiogata@med.kurume-u.ac.jp (K. Ogata).

¹ Present address: Department of Infectious Diseases, Department of Infection Control and Prevention, Faculty of Medicine, University of Tokyo Hospital, Tokyo, Japan.

² Present address: Kofu Municipal Hospital, Yamanashi, Japan.

³ Present address: Second Division of Internal Medicine, Medical Faculty, Kagoshima University, Kagoshima, Japan.

⁴ Present address: Division of Hepatobiliary and Pancreatic Diseases, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan.

1386-6346/\$ – see front matter © 2005 Elsevier Ireland Ltd. All rights reserved.

doi:10.1016/j.hepres.2005.08.012

Conclusions: Our multicenter cooperative survey revealed that medical procedure was the most frequent source of infection in acute hepatitis C. As concerns the therapy, interferon treatment should be initiated within 24 weeks after onset of symptoms.
© 2005 Elsevier Ireland Ltd. All rights reserved.

Keywords: Hepatitis C virus (HCV); Acute hepatitis; Medical procedure; Interferon

1. Introduction

There are about 170 million people infected with the hepatitis C virus (HCV) worldwide [1], and the infection progresses to hepatic cirrhosis in 10–30% [1,2]. Since patients often lack subjective symptoms even in acute hepatitis C [3], infection is often realized by patients when the pathology progresses to hepatic cirrhosis and hepatocellular carcinoma. There are a variety of sources of infection, such as medical procedure, intravenous drug use, and sexual behavior [4,5]. In addition, vertical transmission of HCV has been reported, and it seems that maternal viral load is significant for infection to fetus [6]. On the other hand, as a therapy for acute hepatitis C, interferon (IFN) administration has been established to be effective [4,5,7–13].

Although the initial prevention of hepatitis C virus (HCV) infection is ideal, the most effective method of preventing progression to the chronic hepatitis C is still controversial in the acute phase. In Japan, the development of acute hepatitis C due to blood transfusion has markedly decreased after introduction of the HCV antibody test for screening of blood donors [14]. However, infection from intravenous (i.v.) drug use and incidences due to accidental contamination of medical staff are still important problems [15,16]. Investigation for the sources of infection in acute hepatitis C is very important for the prevention. In this study, we investigated a national survey on the route of infection of acute hepatitis C and the therapeutic effectiveness according to the timing of IFN therapy. This survey consists of the largest number of case reports and may reflect the current situation of acute hepatitis C in Japan.

2. Patients and methods

2.1. Patients

A retrospective study was performed in patients of 12 facilities nationwide who developed acute hepatitis C after 1990. The total number of patients at the facilities was 102. Informed written consent was obtained from each patient, and the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki. Age, gender, source of infection, HCV serotype or genotype, HCV-RNA level, histology of liver biopsy, fluctuation in alanine aminotransferase (ALT) level, presence or absence of IFN therapy, course when not treated with IFN, duration between onset of symptoms and IFN therapy, type of IFN, total dose of IFN, administra-

tion method, total duration of administration, and therapeutic results were investigated in each patient.

2.2. Diagnosis of acute hepatitis C

The diagnostic criteria of acute hepatitis C were HCV-RNA detectable at the time of an elevated ALT level, followed by development conversion of HCV antibody. Patients in whom HCV antibody was already positive at the onset were excluded.

2.3. Natural course

In patients who followed the natural course without any treatments, the chronic hepatitis was defined as persistence of HCV-RNA positivity for 6 months or longer, and resolution was defined as a disappearance of serum HCV-RNA within 6 months followed by persistent negativity for 6 months or longer.

2.4. Definition of fluctuation of ALT

In patients diagnosed with acute hepatitis C, when one peak of the serum ALT level was observed, the fluctuation was designated as monophasic, and when two or more peaks were observed, the fluctuation was designated as bi- or multiphasic.

2.5. Serologic tests

Anti-HCV antibody was determined using a second-generation or third-generation enzyme-linked immunosorbent assay (Ortho Diagnostics Systems, Tokyo, Japan). Hepatitis C virus RNA was quantified by using the bDNA signal amplification assay (Chiron Corp.) or the Cobas Amplicor HCV Monitor test ver1.0 or 2.0 (Roche Diagnostic Systems, Tokyo, Japan). The data were represented as Meq/ml, K copies/ml, and KIU/ml, respectively. Detection of HCV-RNA to determine the response of IFN treatment was used by Amplicor HCV (Roche Diagnostics K.K., Japan). Hepatitis C virus serotype was determined using the genotyping enzyme-linked immunosorbent assay (International Reagents Corporation, Tokyo, Japan) to be type 1 or 2 [17].

2.6. IFN therapy

For IFN, IFN- α (natural form, gene recombinant, or consensus IFN), or IFN- β was used (Table 4). No concurrent treatment with IFN and ribavirin was administered to any patient. Among patients treated with IFN, the sustained

virological response (SVR) was defined undetectable HCV-RNA in serum at least 6 months after cessation of therapy. Non-response was defined as detectable HCV-RNA for 6 months after cessation of therapy.

2.7. Statistical analysis

Data were expressed as the mean \pm standard deviation for continuous variables and as counts for categorical variables. The results were compared using the Chi-square test, Fisher's exact probability test, or Mann-Whitney *U*-test, depending upon the type of data analysed. Logistic regression was used to analyse the factors contributing to SVR with IFN therapy. *P* values <0.05 were considered significant. Statistical analyses were performed by using Stat View software (version 5.0; SAS Institute Inc., Cary, NC).

3. Results

3.1. Patient characteristics

The baseline characteristics of the 102 patients in this study are shown in Table 1. The distribution of patients by gender and age is shown in Table 2.

3.2. Natural course

The natural course of the disease was followed in 21 patients, and the course could be followed to the outcome

Table 2
Distribution of patients according to gender and age

Age (years)	Number of patients					
	Medical procedure (M/F)	Accidental needlestick (M/F)	Sexual behavior (M/F)	Drug abuse (M/F)	Tattoo (M/F)	Unknown (M/F)
<19	0/1	0/0	0/0	0/1	0/0	0/1
20–29	5/1	3/8	1/3	2/1	3/0	2/6
30–39	4/3	3/3	2/1	0/1	0/0	3/3
40–49	2/4	0/4	1/0	0/1	0/0	2/3
50–59	4/3	0/0	0/0	0/0	0/0	2/3
60–69	4/1	0/0	0/0	0/0	0/0	2/0
70–79	0/0	0/0	0/0	0/0	0/0	1/1
>80	0/1	0/0	0/0	0/0	0/0	0/2
Total	19/14	6/15	4/4	2/4	3/0	12/19

M, male, F, female.

Table 3
Base-line characteristics of 18 untreated patients

	Resolved group (seven cases)	Chronic group (11 cases)	<i>P</i> value
Age	64.4 \pm 15.2	45.6 \pm 14.3	0.0331 ^a
Gender (male/female)	2/5	4/7	>0.9999
HCV RNA level (high ^b /low/N.D.)	2/4/1	6/4/1	0.6084
Serogroup (1/2/N.D.)	4/0/3	4/2/5	0.4667
Fluctuation of ALT level (monophasic/bi- or multiphasic/N.D.)	5/0/2	0/8/3	0.0008 ^a

N.D., not determined; ALT, alanine aminotransferase. Fluctuation of ALT level: monophasic; one peak of the serum ALT was observed, bi- or multiphasic; two or more peaks of the serum ALT were observed (N.D. was excluded from statistical comparisons).

^a Statistically significant.

^b Viral load (high): more than 100 KIU/ml or 1 Meq/ml.

Table 1
Base-line characteristics of 102 patients

Age	38.6 \pm 16.2 (16–84)
Male/female (mean age)	46 (39.2 \pm 16.0)/56 (38.2 \pm 16.5)
Source of infection (%)	
Medical procedure	33 (32.4)
Accidental needle stick	21 (20.6)
Sexual behavior	8 (7.8)
Drug abuse	6 (5.9)
Tattoo	3 (2.9)
Unknown	31 (30.4)
Viral load (high ^a /low/N.D.)	46/45/11
HCVserotype(1/2/N.D.)	54/23/25
IFN/without IFN	81/21

N.D., not determined; IFN, interferon. Details of the routes in medical procedure: surgery 14, blood transfusion 5, endoscopy 3, intravenous injection 4, invasive procedure 3, dental therapy 3, dialysis 1.

^a Viral load (high): more than 100 KIU/ml or 1 Meq/ml.

in 18 patients (the prognosis was unknown in three patients) (Table 3). The disease progressed to chronic hepatitis C in 61.1% of the patients and resolved spontaneously in 38.9% of the patients. The age and the fluctuation pattern of the ALT level were significantly different between the two groups. As for gender, serum HCV-RNA level, and serogroup, no correlation with spontaneous resolution or chronic hepatitis C was observed.

3.3. IFN therapy

Table 4 shows the backgrounds of the 81 patients treated with IFN. Of 71 patients in whom the effect was clarified,

Table 4
Base-line characteristics of 81 patients treated with interferon

Age	38.6 ± 16.2
Gender (male/female)	43/38
HCV RNA level (high ^a /low/N.D.)	38/36/7
HCV serogroup (1/2/N.D.)	46/21/14
Fluctuation of ALT level (monophasic/bi- or multiphasic/N.D.)	21/53/7
Type of IFN (α/β)	63/18
Total IFN dose (MU)	470 ± 228.1 (52–972)
Duration of IFN administration (w)	17.6 ± 8.9 (4.0–42.0)
Outcome (SVR ^b /NR/N.D.)	57/14/10

N.D., not determined; ALT, alanine aminotransferase; IFN, interferon; MU, million units; SVR, sustained virological response; NR, non-response: detectable HCV RNA in serum for 6 months after cessation of therapy.

^a HCV RNA level (high): more than 100 KIU/ml or 1 Meq/ml.

^b Sustained virological response: undetectable HCV RNA in serum at least 6 months after cessation of therapy.

57 patients (80.3%) had SVR. Table 5 shows the results of the logistic regression analysis of SVR-related factors. Age, gender, serogroup, HCV-RNA level, fluctuation of ALT, duration between onset and initiation of IFN, type of IFN, total IFN dose, and duration of IFN administration were evaluated statistically by univariate and multivariate analysis. On multivariate analysis as well as univariate analysis, the duration between onset of symptoms and initiation of IFN therapy was the only factor related to SVR.

The SVR rate according to the duration before initiation of IFN therapy was investigated (Fig. 1), and the SVR rate was found to be significantly higher in patients treated before 24 weeks than in patients treated after 25 weeks. However, immediate administration has not been associated with higher SVR rate (0–8 weeks versus 9–24 weeks).

On comparison of the SVR rate by the source of infection, the SVR rate was 100% in the patients infected by accidental needlestick (19/19) (the prognosis was unknown in two of 21 patients infected by needlestick). This was significantly higher than that in patients infected via other routes (19/19




Fig. 1. Sustained virological response rate according to duration between onset of symptoms and initiation of IFN therapy. The groups treated with IFN 0–24 weeks after onset of symptoms and treated after 25 weeks were compared. Comparison by the Chi-square test. (*) Statistically significant; w, week.

versus 38/52, $P < 0.05$). The duration between onset of symptoms and initiation of IFN therapy was investigated according to the source of infection, and the duration was shortest in the needlestick group (9.7 ± 5.3 weeks).

4. Discussion

We examined the source of infection and optimal timing of therapy in patients with acute hepatitis C at 12 facilities in Japan. Since there has been no study performed in more than 100 patients with acute hepatitis C in Japan, this study may reflect the current situation in Japan. HCV serogroup of 25 patients were not determined (Table 1). Several reasons are considered. Firstly, the study is retrospective. Secondly,

Table 5
Logistic regression analysis of odds ratio for sustained virological response

Variable	Odds ratio	95% CI	P value
Univariate			
Age(40>/40≤)	2.48	0.73–8.46	0.147
Gender (female/male)	2.48	0.74–8.33	0.143
Serogroup (1/2)	1.03	0.23–4.54	0.969
HCV RNA level (high ^a /low)	1.75	0.46–6.68	0.413
Fluctuation of ALT (monophasic/bi-or multiphasic)	1.57	0.38–6.45	0.531
Duration between onset and initiation of IFN (≤24w/≥25w)	7.50	1.85–30.48	0.005 ^b
Type of IFN (alpha/beta)	4.33	0.52–36.18	0.176
Total IFN dose (>300MU/≤300MU)	2.27	0.63–8.15	0.208
Duration of IFN administration (≥24w/<24w)	1.43	0.44–4.67	0.551
Multivariate			
Duration between onset and initiation of IFN (≤24w/≥25w)	15.78	1.37–181.61	0.027 ^b

ALT, alanine aminotransferase; IFN, interferon; MU, million units; 95% CI, 95% confidence interval.

^a HCV RNA level high: More than 100 KIU/ml or 1 Meq/ml.

^b Statistically significant.

titer of anti-HCV is often low in early phase of acute hepatitis C. Many patients were considered to be infected during a medical procedure. Studies on risk of surgery for the development of acute hepatitis C have been reported previously [18]. Alfonso et al. performed a large-scale surveillance in Italy and found that 25.5% of patients (261/1023) with acute hepatitis C had undergone an invasive procedure. Therefore, medical care should be recognized as an important source of infection in the sporadic incidence of acute hepatitis C. On the other hand, in blood donors of Western Mexico, the most frequent risk factors for HCV transmission were transfusion (42%) and household exposure (14.8%) [19]. Therefore, the main risk factors for infection may differ with countries.

Since IFN therapy for acute hepatitis C is not covered by the health care insurance, the therapy could not be administered to all patients. The progression to the chronic hepatitis C in the 18 patients with natural courses without IFN therapy was almost consistent with previous reports [20,21]. As shown in Table 3, a significant difference was observed in age, but this may have been due to the two patients in their 80s in the spontaneous resolution group (data not shown). The important point is that the ALT fluctuation was monophasic in all patients in the spontaneous resolution group. In contrast, the fluctuation was bi- or multiphasic in patients who progressed to chronic hepatitis C. As a characteristic of acute hepatitis C in which spontaneous elimination of the virus is likely to occur, it has been reported that many cases are accompanied by subjective symptoms, such as jaundice and influenza-like symptoms [22,23]. Subjective symptoms are sometimes influenced by the patient's subjective sense. In contrast, the fluctuation of the ALT level may be a more objective index. Hofer et al. observed the natural course for at least 30 days after onset, and when serum HCV-RNA became negative during this period, the disease was resolved at a high rate, suggesting that IFN therapy should be administered to patients in whom negative conversion of HCV-RNA did not occur within 30 days [22]. Combined with our results, it might be likely that the disease resolves spontaneously in patients in whom the ALT level followed the monophasic course, as well as in those in whom the disease is symptomatic and negative conversion of HCV-RNA occurs in the early stage.

As the results of IFN therapy, the SVR rate was 80.3% (57/71) as shown in Table 4. Our present study, albeit retrospective analysis, revealed that therapy initiated within 24 weeks was the only factor related to the SVR in both univariate and multivariate analysis (Table 5). In the randomized controlled study by Hwang et al., the factor related to SVR was the HCV-RNA level before initiation of therapy [9]. However, there were only 33 patients, which may have led to a result different from our results. On the other hand, Nomura et al. recently performed a randomized controlled trial in patients with acute hepatitis C, and their results demonstrate that the SVR rate was significantly higher in the early-intervention group (IFN therapy was initiated 8 weeks

after the onset) than in the late-intervention group (IFN therapy was initiated after 1 year observation from the onset) (87% versus 40%) [24]. Otherwise, Gruner et al. prospectively investigated the T-cell dynamics in patients with acute hepatitis C, and found that activity of HCV-specific IFN- γ -producing T cells started to decrease 24 weeks after onset [25]. In addition, T cell actions have been reported to be important for elimination of HCV in the early stage of infection [26–30], and the defective functions of HCV-specific T cells might contribute to viral persistence in chronically infected patients [31]. It is interesting that our results support their reports.

Next, we evaluated the optimal timing of initiation of therapy within 24 weeks. In our previous study, we administered therapy after observation of the course for about 4 weeks when signs of the chronic hepatitis began to appear, not immediately after the onset, and obtained good results [32,33]. Licata et al. investigated the optimum timing of IFN therapy by meta-analysis [34]. Their analysis shows that delaying therapy 2 months after the onset of the disease does not affect the efficacy of treatment, therefore, they suggest that patients should be treated within 60 days from the onset to avoid the unnecessary treatment of affected patients who would spontaneously recover. In our study, the highest SVR rate was obtained in the group treated 9–12 weeks after onset of symptoms as shown in Fig. 1, which was consistent with their analytical results.

The SVR rate obtained by combination therapy with Pegylated-IFN (Peg-IFN) and ribavirin for chronic hepatitis C was 30–54% [35–37], but for acute hepatitis C, the therapeutic result was good even when IFN was administered alone. To elucidate this difference, it may be important to investigate not only the T-cell dynamics but also viral genome in various aspects [7]. In our present study, no patients were treated with Peg-IFN. Recently, the efficacy of Peg-IFN monotherapy with acute hepatitis C has been reported. Santantonio et al. evaluated the delaying Peg-IFN therapy, targeting sixteen patients who failed to spontaneously clear the virus within 12 weeks from the onset. They reported that 15/16 patients (94%) showed SVR [38]. Since the highest SVR was obtained in the group treated 9–12 weeks after onset in our study, it is important to start the IFN therapy in optimal timing regardless of the kind of IFN. The high SVR has been obtained by IFN monotherapy, so that, it is necessary to investigate whether ribavirin should be administered concurrently with IFN.

In conclusion, the major sources of infection of acute hepatitis C in Japan were the medical procedure and accidental needlestick. The disease may be likely to resolve spontaneously in patients in whom fluctuation of the ALT level follows the monophasic course. The SVR rate was significantly higher in the group treated with IFN within 24 weeks after the onset of symptoms than in the group treated after 25 weeks. In cases of acute hepatitis C, it is desirable to administer IFN at least within 24 weeks when the ALT level starts to follow a multiphasic course.

Acknowledgments

This study was supported, in part, by a grant-in-aid from the Ministry of Health, Welfare, and Labour of Japan. The authors thank Kendo Kiyosawa, M.D., Keisuke Hino, M.D., Kyosuke Kaji, M.D., Akihiro Iwamitsu, M.D., Tomoo Naito, M.D., Yasuhito Tanaka, M.D., for assistance with data collection.

References

- [1] Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. *Semin Liver Dis* 2000;20:17–35.
- [2] Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. *Lancet* 1997;349:825–32.
- [3] Alberti A, Boccardo S, Vario A, Benvegna L. Therapy of acute hepatitis C. *Hepatology* 2002;36(Suppl.):195–200.
- [4] Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. *N Engl J Med* 2001;345:1452–7.
- [5] Komine F, Yamaguchi T, Moriyama M, et al. A case of sexually transmitted acute hepatitis C: confirmation by analysis of viral genome. *Hepatol Res* 1999;14:84–91.
- [6] Kowala-Piaskowska A, Figlerowicz M, Mozer-Lisewska I, et al. Vertical transmission of hepatitis C virus infection. *Hepatol Res* 2004;30:137–40.
- [7] Saito T, Watanabe H, Shao L, et al. Transmission of hepatitis C virus quasi species between human adults. *Hepatol Res* 2004;30:57–62.
- [8] Omata M, Yokosuka O, Takano S, et al. Resolution of acute hepatitis C after therapy with natural beta interferon. *Lancet* 1991;338:914–5.
- [9] Hwang SJ, Lee SD, Chan CY, Lu RH, Lo KJ. A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C. *J Hepatol* 1994;21:831–6.
- [10] Takano S, Satomura Y, Omata M. Effects of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. *Gastroenterology* 1994;107:805–11.
- [11] Lampertico P, Rumi M, Romeo R, et al. A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C. *Hepatology* 1994;19:19–22.
- [12] Vogel W, Graziadei I, Umlauf F, et al. High-dose interferon- α 2b treatment prevents chronicity in acute hepatitis C. A pilot study. *Dig Dis Sci* 1996;41(Suppl.):81–5.
- [13] Camma C, Almasio P, Craxi A. Interferon as treatment for acute hepatitis C. A meta-analysis. *Dig Dis Sci* 1996;41:1248–55.
- [14] Japanese Red Cross non A, non B-hepatitis Research Group. Effect of screening for hepatitis C virus antibody and hepatitis B virus core antibody on incidence of post-transfusion hepatitis. *Lancet* 1991;338:1040–1.
- [15] Noguchi S, Sata M, Suzuki H, Ohba K, Mizokami M, Tanikawa K. GB virus C (GBV-C)/hepatitis G virus (HGV) infection among intravenous drug users in Japan. *Virus Res* 1997;49:155–62.
- [16] Kiyosawa K, Sodeyama T, Tanaka E, et al. Hepatitis C in hospital employees with needlestick injuries. *Ann Intern Med* 1991;115:367–9.
- [17] Tanaka T, Tsukiyama-Kohara K, Yamaguchi K, et al. Significance of specific antibody assay for genotyping of hepatitis C virus. *Hepatology* 1994;19:1347–53.
- [18] Mele A, Spada E, Sagliocca L, et al. Risk of parenterally transmitted hepatitis following exposure to surgery or other invasive procedures: results from the hepatitis surveillance system in Italy. *J Hepatol* 2001;35:284–9.
- [19] Vivas-Arceo C, Benavides SA, De Jesus Trujillo J, et al. Hepatitis C virus: prevalence and routes of infection among blood donors of West Mexico. *Hepatol Res* 2003;25:115–23.
- [20] Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. *N Engl J Med* 1992;327:1899–905.
- [21] Tanaka E, Kiyosawa K. Natural history of acute hepatitis C. *J Gastroenterol Hepatol* 2000;15(Suppl.):97–104.
- [22] Hofer H, Watkins-Riedel T, Janata O, et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. *Hepatology* 2003;37:60–4.
- [23] Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. *Gastroenterology* 2003;125:80–8.
- [24] Nomura H, Sou S, Tanimoto H, et al. Short-term interferon- α therapy for acute hepatitis C: a randomized controlled trial. *Hepatology* 2004;39:1213–9.
- [25] Gruner NH, Gerlach TJ, Jung MC, et al. Association of hepatitis C virus specific CD8⁺ T cells with viral clearance in acute hepatitis C. *J Infect Dis* 2000;181:1528–36.
- [26] Diepolder HM, Zachoval R, Hoffmann RM, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. *Lancet* 1995;346:1006–7.
- [27] Missale G, Bertoni R, Lamonaca V, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. *J Clin Invest* 1996;98:706–14.
- [28] Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. *J Exp Med* 2001;194:1395–406.
- [29] Thimme R, Bukh J, Spangenburg HC, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. *Proc Natl Acad Sci USA* 2002;99:15661–8.
- [30] Ulsenheimer A, Gerlach JT, Gruener NH, et al. Detection of functionally altered hepatitis C virus-specific CD4⁺ T cells in acute and chronic hepatitis C. *Hepatology* 2003;37:1189–98.
- [31] Wedemeyer H, He XS, Nascimbeni M, et al. Impaired effector function of hepatitis C virus-specific CD8⁺ T cells in chronic hepatitis C virus infection. *J Immunol* 2002;169(6):3447–58.
- [32] Sata M, Hashimoto O, Noguchi S, et al. Transmission routes and clinical course in sporadic acute hepatitis C. *J Viral Hepat* 1997;4:273–8.
- [33] Sata M, Ide T, Noguchi S, et al. Timing of IFN therapy initiation for acute hepatitis C after accidental needlestick. *J Hepatol* 1997;27(2):425–6.
- [34] Licata A, Bona DD, Schepis F, Shahied L, Craxi A, Camma C. When and how to treat acute hepatitis C? *J Hepatol* 2003;39:1056–62.
- [35] Heathcote EJ, Schiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. *N Engl J Med* 2000;343:1673–80.
- [36] Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. *N Engl J Med* 2000;343:1666–72.
- [37] Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001;358:958–65.
- [38] Santantonio T, Fasano M, Sinisi E, et al. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. *J Hepatol* 2005;42:329–33.

Effect of Bezafibrate on Non-responders to UDCA in Patients with Chronic Hepatitis C

Susumu Shiomi¹⁾, Daiki Habu¹⁾, Etsushi Kawamura¹⁾,
Masaru Enomoto¹⁾, Akihiro Tamori¹⁾ and Shuhei Nishiguchi²⁾

ABSTRACT

Objective Ursodeoxycholic acid (UDCA) has been widely used in the treatment of chronic hepatitis C, however, the effectiveness of this drug is limited. We evaluate the effectiveness of additional bezafibrate treatment in patients who had not responded to treatment with UDCA.

Materials and Methods The subjects were 50 patients with chronic hepatitis C whose alanine aminotransferase (ALT) level was over 60IU/L after 12-week or longer treatment with UDCA (300 or 600mg/day). Two treatment regimens (UDCA treatment alone (300-600mg/day) were continued for 16 weeks, followed by 16 weeks of treatment with a combination of UDCA and bezafibrate (400mg/day)). The two regimens were applied following a cross-over study design. During the study period, liver function tests and HCV-RNA titer were conducted every 8 weeks.

Results In both groups, ALT, γ -GTP, and ALP levels during the combined bezafibrate and UDCA treatment period were significantly lower than levels before the start of the study or at the end of the UDCA treatment period. Neither of two groups showed a significant change in HCV-RNA titer. In multivariate analysis, platelet count was the indicator used to determine drug effectiveness.

Conclusions In the present study, combined UDCA and bezafibrate therapy improved liver function tests such as ALT but failed to reduce HCV-RNA titer in patients who had not responded to treatment with UDCA. (Jpn Pharmacol Ther 2006 ; 34 : 71 - 8)

KEY WORDS Bezafibrate, Chronic hepatitis C, Ursodeoxycholic acid (UDCA), Liver function test, HCV-RNA

INTRODUCTION

Hepatocellular carcinoma (HCC) has been the third leading cause of death from malignant neoplasms in men for the last 30 years in Japan. The increase in the incidence of HCC, however, can be largely attributed to hepatitis C virus (HCV) infection and the increase of this disease in the general population during the last 50 to 60 years¹⁾. Moreover, there are about 1.5million patients with chronic hepatitis C, the most common chronic liver disease in Japan. Although interferon (IFN) therapy is used extensively for the treatment of chronic hepatitis C, its effectiveness is limited.

¹⁾ Departments of Nuclear Medicine, and Hepatology, Graduate School of Medicine, Osaka City University

²⁾ Division of Hepatobiliary and

Pancreatic Diseases Department of Internal Medicine, Hyogo College of Medicine